TRANSACTIONS - CEC CAPITAL

Cancel

Date：2022-12
/index.php?a=shows&catid=34&id=719
Sinovation (Beijing) Medical Technology Co., Ltd. (referred to as Sinovation), a leading Chinese intelligent platform for minimally invasive neurosurgery, recently announced the closing of nearly RMB 300 million in Series D financing. The round was led by
Cancel

Date：2022-12
/index.php?a=shows&catid=34&id=721
BioMérieux recently entered a strategic investment partnership with Accunome Biotechnology Co., Limited ("Accunome"), which includes an equity investment and an exclusive distribution agreement. This partnership signifies a deep collaboration between BioM
Cancel

Date：2022-12
/index.php?a=shows&catid=34&id=720
Ronovo Surgical (Shanghai) Medical Technology Co., Ltd. ("Ronovo Surgical” or “Ronovo") completes a financing round of tens of millions of dollars. The round was led by LongRiver Investments, with participation from existing investors including Lilly AsiaVentures, Vivo Capital, Matrix Partners China, GGV Capital, who continue to show strong confidence and support in the company's development. CEC Capital acted as the exclusive financial advisor for this financing round.
Cancel

Date：2022-11

Exclusive Financial Advisor to VIVEST
Cancel

Date：2022-09
/index.php?a=shows&catid=34&id=722
Ubrigene (Beijing) Biology Technology Co., Ltd. (“Ubrigene”) has recently completed its Series C financing in the hundreds of millions RMB. The round was led by the National Strategic Transformation and Upgrading Fund under Jingshi Investment, Jingshi Kangjian Fund, and Lyon Capital's flagship China market USD fund. Also participating were Huada Gongying, Xing Investment Capital, Wenzhou Investment, Yuan Chuang Capital, as well as existing shareholders, including Huagai Capital, Fangfu Capital, and IDG Capital. CEC Capital served as the exclusive financial advisor to Ubrigene in this transaction.
Cancel

Date：2022-09
/index.php?a=shows&catid=34&id=725
Worg Pharmaceuticals, a biopharmaceutical company dedicated to providing breakthrough immune therapy solutions, announced the successful closing of nearly RMB 400 million in its Series B financing. Investors in this round of funding included Junson Capita
Cancel

Date：2022-09
/index.php?a=shows&catid=34&id=727
BoomRay Pharmaceuticals is at the forefront of creating next-generation targeted radionuclide-conjugated drugs. HongShan led this round, with participation from Riverhead Capital, Tririver Capital, Puhua Capital, Tsing Song Capital, Life Sciences Investme
Cancel

Date：2022-08
/index.php?a=shows&catid=34&id=728
Raintech, a leading smart IoT production management platform for greenhouses, announced the successful closing of its Series A financing, with Shunwei Capital investing millions of RMB. The funds will be primarily used for product research and development
Cancel

Date：2022-06
/index.php?a=shows&catid=34&id=729
Therorna Inc. is dedicated to the development of novel vaccines and therapies in multiple cutting-edge treatment areas, focusing on international frontier circular RNA (circRNA) technology. This funding round was led by MSA Capital and a renowned industri